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Abstract
Background: The neuronal guidance molecule Slit2 plays suppressive role in tumorigenesis and progression. We
previously showed that Slit2-Robo1 inhibit cell migration in colorectal cancer (CRC). However, little is known about
its downstream effectors in CRC. This study tries to identify whether the Slit-Robo Rho GTPase activating protein
1 (srGAP1) could mediate the inhibitory effect of Slit2-Robo1 on CRC cell migration.
Methods: The protein expression of srGAP1 in clinical CRC tissues was tested by immunohistochemistry staining.
Conditioned medium was prepared from HEK293 cells stably expressing Slit2-myc, Robo1-HA or RoboN (a soluble
extracellular domain of Robo1). Immunoprecipitation (IP) was applied to check the interaction between Robo1 and
srGAP1, and immunofluorescence (IF) was used to observe the subcellular localization of Robo1 and srGAP1. Small
GTPase pull-down assay was used to determine the activity of Cdc42. A modified wound healing assay was
performed to detect cell migration.
Results: The protein expression of srGAP1 was remarkably decreased in 47.5% of CRC tissues compared with
adjacent noncancerous tissues, and the decreased srGAP1 expression was associated with lymphatic invasion,
poor tumor differentiation, high TNM stage, and poor survival (P < 0.05). IP and IF assays revealed that srGAP1
was a Robo1-interacting protein and exhibited similar dynamic subcellular distribution after Slit2 treatment in
CRC cells. Small GTPase pull-down assay and migration assay indicated that Slit2-Robo1 signaling inhibited
Cdc42 activity and CRC cell motility through srGAP1.
Conclusion: Downregulation of srGAP1 in CRC was associated with tumor progression and poor prognosis.
srGAP1 is an important downstream molecule of Slit2 signalling in CRC, and mediates the anti-migration function
of Slit2 by inhibiting Cdc42.
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Background
Colorectal cancer (CRC) is one of the most common
cancer worldwide [1]. The incidence of CRC persistently
increases in China and other developing countries, and
CRC remains as an important health concern worldwide
[2]. High motility ability of CRC cells is a key factor to
prompt tumor metastasis, which is one of the key reasons
resulting in therapy failure and cancer-related death.
Tumor progression requires increased cell motility,
which is accompanied by increased actin polymerization
and enhanced activity of proteins that optimize its
turnover. Previous studies have showed that Slit-Robo
signaling affects cell motility by controlling the activity
of several proteins involved in reorganizing the actin
cytoskeleton, including the Rho GTPases family (Rac,
Cdc42, and RhoA) [3].
Slits are secreted extracellular matrix proteins expressed
in many types of cells and tissues. As the key neuronal
guidance molecules, Slits were originally identified to
regulate axonal guidance and neuronal migration in the
central nervous system by binding to Roundabout recep-
tor family (Robo1-Robo4) [4, 5]. In addition to their
functions in nervous system, recent data revealed that
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Slit-Robo pathway also plays key roles in human tumori-
genesis and progression [3].
Slit2 is the most common studied member of Slit family
and exerts its activity mainly by binding to Robo1. Slit2 is
frequently downregulated in many types of cancers and
exhibits tumor suppressive functions, especially inhibition
of tumor cell migration. Although Zhou et al. [6] reported
that Slit2 could prompt CRC tumorigenesis and metasta-
sis, our recent work showed that Slit2 is frequently down-
regulated in clinical CRC tissues and inhibits CRC cell
migration in a Robo-dependent manner [7]. Dallol et al.
[8] and Chen et al.[9] also reported the tumor suppressive
role of Slit2 in CRC. However, little was known about the
detailed regulation mechanism of Slit2-Robo1, especially
its downstream targets in CRC.
The Slit-Robo Rho GTPase activating protein 1 (srGAP1)
is a key GTPase activating protein (GAP) downstream of
Slit-Robo pathway, and has been shown to inhibit neuronal
migration [10] and glioma cell invasion [11] by reducing
the activation of Cdc42. Whether srGAP1-Cdc42 axis is a
key downstream functional target of Slit2 signaling in CRC
remains to be elucidated and little was known about the
expression and clinical significance of srGAP1 in human
cancer.
In this study, we identify that srGAP1 is a key Robo-
interacting protein and mediates the migration inhibitory
function of Slit2 by inhibiting Cdc42 activity in CRC. Clin-
ical sample analyses revealed that srGAP1 was significantly
downregulated in CRC tissues, which was associated with
tumor progression and poor patient survival.
Methods
Tumor tissues and cell lines
A total of 156 human primary CRC tissues and their
adjacent noncancerous tissues (NCT) were collected
with informed consent at Affiliated Hospital of Jiangnan
University, and the detailed clinical information of these
patients was included in Table 1. This project was ap-
proved by the Clinical Research Ethics Committee of the
Affiliated Hospital of Jiangnan University.
Human CRC cell lines (HCT8, HCT116, LoVo, Caco2,
DLD1, and HT29) and HEK293 cell line were purchased
from American Type Culture Collection (ATCC). All of
the culture media (Hyclone, USA) were supplemented
with 10% fetal bovine serum (FBS) (Clark, Australia).
These cells were incubated under the conditions recom-
mended by ATCC.
Antibodies and plasmids
Mouse anti-β-actin (A1978), anti-β-tubulin (T8328)
and anti-Flag (F1804) from Sigma-Aldrich (USA);
mouse anti-HA (16B12, MMS-101R), anti-myc (9E10,
MMS-101R) and rabbit anti-GFP (NB600-308) from
Covance Laboratories Ltd (UK); anti-Cdc42 from BD
Transduction Laboratories (No.610929, USA); anti-Robo1
from Abcam (ab7279, USA), anti-srGAP1 from Protein-
tech (13252-1-AP, USA). The plasmid constructs of
Robo1-HA, Robo1-myc, Robo1-RFP, RoboN (a soluble
extracellular domain of Robo1), srGAP1-Flag, srGAP1-
GFP, srGAP1ΔGAP (Δ320–570), GFP-USP33, CACdc42
(constitutively active), DNCdc42 (dominant negative), and
GST-PAK1 were generated as described [5, 10, 12].
Plasmid transfection was performed using Lipofectamine
2000 (Invitrogen, USA).
Immunohistochemistry (IHC) staining
Tissue arrays were constructed using 156 paired CRC
tissues and NCTs. The protein expression of srGAP1
was measured by IHC method that was performed on
4 μm paraffin-embedded CRC tissue sections. In brief,
the slides were hatched with anti-srGAP1 antibody at a
dilution of 1:100 overnight at 4 °C, followed by 1 h incu-
bation of secondary antibody. The subsequent steps
were performed using GTvisionTM III Detection System/
Mo&Rb (DAKO, USA). The protein expression of
srGAP1 was scored 0, and 1, 2, and 3 according to the
percentage and staining intensity of positive colorectal
epithelium cells.
Table 1 srGAP1 protein expression in CRC tissues
Characteristics Number srGAP1 score p value
0 or 1 2 or 3
Ages (years)
≥ 65 76 44 32 0.602
< 65 80 43 37
Gender
Male 70 39 31 0.990
Female 86 48 38
Tumor size (cm) 0.733
< 5 79 43 36
≥ 5 77 44 33
Differentiation 0.024
Well 14 3 11
Moderately 110 64 46
Poorly 32 20 12
Nodal status
Positive 78 36 42 0.016
Negative 78 51 27
TNM stage
I + II 75 34 41 0.012
III + IV 81 53 28
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Conditioned medium (CM)
HEK293 cells stably expressing Slit2-myc, Robo1-HA or
RoboN were established as previously described [5]. To
generate CM, these HEK293 stable cells were plated in
10 cm2 dishes and grown to approximately 80% conflu-
ence in normal growth medium, and were then incubated
in 8 mL of DMEM medium supplemented with 5% FBS
for 48 h. The supernatant was collected, centrifuged and
then stored in −80 °C until use. In some experiments, CM
was concentrated using Amicon Ultra centrifugal filtration
devices (Millipore, USA), and working concentrations of
Slit2 in CM was estimated to be 100 ~ 250 ng/mL accord-
ing to the silver staining of serial dilutions of CM follow-
ing SDS-PAGE fractionation.
RNA extraction and RT-PCR
Total RNA was extracted using the RNAiso Plus (Takara,
Japan) according to the manufacturer’s instructions.
The concentrations of RNA were measured by NanoDrop
ND-2000 instrument (NanoDrop, USA) and complemen-
tary DNA (cDNA) was synthesized using the HiFiScript
cDNA Kit (CWBIO, China). RT-PCR was used to detect
gene expression in CRC cell lines, with β-actin as an in-
ternal control. The primers used were described in our
previous study [7].
Western blot and immunoprecipitation (IP)
Western blot was performed as previously described [7],
and the dilution ratios for different primary antibodies
were 1:3000 (anti-β-actin, anti-β-tubulin, anti-Flag, anti-
HA, and anti-myc), 1:2000(anti-GFP), 1:1000(anti-Cdc42,
anti-Robo1 and anti-srGAP1). For IP assay, plasmid con-
structs of Robo1-HA, srGAP1-GFP, srGAP1-Flag, USP33-
GFP or control vector were transfected into CRC cells.
Forty-eight hours after transfection, cells were lysed using
IP lysis buffer (1% Triton-100, 10% Glycerol, and 1 mM
EDTA in TBS buffer), and IP was performed using anti-
HA or anti-Flag as described previously [5].
Immunofluorescence (IF)
CRC cells were cotransfected with plasmids of Robo1-RFP,
srGAP1-GFP or control. Forty-eighty hours after transfec-
tion, cells were treated with mock or Slit2 CM for 10 min
and were then fixed with 4% paraformaldehyde at room
temperature for 30 min. The images were obtained with an
inverted fluorescence microscope (Olympus, Japan).
Small GTPase pull-down assay
GST-PAK1 fusion protein was expressed in E. coli (BL21
strain), and purified by glutathione-sepharose affinity chro-
matography. Purified GST-PAK1 protein was incubated
with GST-sepharose beads and used for GST pull-down
assay to detect the GTP-loading of Cdc42 (GTP-Cdc42).
To study the potential regulation of Slit2 on Cdc42
activity in CRC, different plasmids were transfected into
CRC cells. Forty-eighty hours after transfection, cells
were lysed in ice-cold IP lysis buffer and were subjected
to GST pull-down assay. Briefly, total cell lysates were
incubated with GST-sepharose beads loaded with GST-
PAK1 protein at 4 °C for 2 h. The beads were washed
three times with lysis buffer. Bounded proteins were
eluted by incubation in sample buffer at 95 °C for
10 min and separated by 15% polyacrylamide gel electro-
phoresis. Bounded Cdc42 was analyzed by Western blot
using an anti-Cdc42 antibody.
Cell migration assay
A modified wound healing assay was performed to detect
cell migration as we described previously [7]. Briefly,
photo-etched grid coverslips (Bellco Biotechnology, USA)
were coated with 10 μg/mL poly-L-lysine, and cells were
then seeded on the coated coverslips and grown to conflu-
ence in the 3.5 cm dish. A wound scratch was made by
scraping a micropipette tip across the cell monolayer.
After removing the dislodged cells by gentle washing with
culture media, cells were treated with CM for 10 h. At 0 h
and 10 h after wound formation, phase-contrast images of
the wound-healing process were photographed under an
inverted microscope. Ten representative images were
taken at the corresponding positions marked by letters on
the etched grid coverslips, and the directional cell migra-
tion was measured as the forward distance that individual
cells migrated from the wound edge line at the zero time
point.
Statistical analysis
The results are presented as the mean values ± SEM.
The data were subjected to χ2 test, Student’s t-test, the
Mann–Whitney U test or the Spearman Rank correl-
ation test. Kaplan-Meier survival analyses and the log-
rank test were carried out to determine differences in
overall survival (OS). The Cox proportional hazards
model was used to estimate hazard ratios (HRs) and
their 95% confidence intervals (CIs), representing the
overall relative risk of death. A P value of less than 0.05
was considered statistically significant. The Graphpad
prism 5.0 software (GraphPad Software, USA) and SPSS
20.0 package (IBM, USA) were used for the statistical
analyses and scientific graphing, respectively.
Results
srGAP1 is downregulated in CRC and is associated with
poor survival
Little was known about the expression and clinical
significance of srGAP1 in human cancers, including
CRC, so we measured the protein levels of srGAP1 in
156 paired CRC and NCT tissues by IHC staining. The
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srGAP1 expression results were not available in 34 NCT
samples due to technical difficulty in the tissue micro-
array construction and IHC staining. As shown in Fig. 1a,
srGAP1 was expressed mainly in cytoplasm and was sig-
nificantly downregulated in 47.5% (58 of 122) of CRCs
compared with NCTs (Fig. 1b). To evaluate the clinical
significance of srGAP1 in CRC, the potential relation-
ships between srGAP1 expression and patients’ clinico-
phathological characteristics were analyzed (Table 1).
Noticeably, srGAP1 expression in CRCs was significantly
correlated with tumor differentiation (Spearman r =
−0.162, P = 0.044), lymphatic invasion (Spearman r =
−0.194, P = 0.015) and TNM stage (Spearman r =
−0.202, P = 0.011), suggesting that srGAP1 expression
was associated with tumor progression.
Survival analysis showed that patients with low
srGAP1 expression (score 0 or 1) had a significantly
poorer OS than patients with high srGAP1 expression
(score 2 or 3) (χ2 = 7.815, P = 0.005, Fig. 1c). Univariate
analysis on these 156 CRCs showed that relative low
srGAP1 expression, positive nodal status, poor differen-
tiation and higher TNM stage were correlated with de-
creased survival time (Table 2). The four parameters
were then subjected to a Cox multivariate analysis. After
adjusting for nodal status, tumor differentiation and
TNM stage, multivariate analyses revealed that patients
with high srGAP1 expression show a trend of prolonged
survival time as compared to patients with low srGAP1
expression (HR = 0.613; 95% CI, 0.360–1.041, P = 0.070)
(Table 2). Collectively, these data suggest the tumor sup-
pressive role of srGAP1 in CRC.
Slit2, Robo1 and srGAP1 expression in CRC cell lines
The mRNA levels of Slit2, Robo1 and srGAP1 were de-
tected in CRC cell lines using RT-PCR. The results re-
vealed that both Slit2 and Robo1 were expressed in HT29
and LoVo cells, whereas srGAP1 mRNA expressed in all
these six CRC cell lines with lowest expression in HT29
cells (Fig. 2a). Western blot results confirmed the Robo1
expression in HT29 and LoVo cells, whereas no detectable
srGAP1 protein was observed in HT29 cells (Fig. 2b).
Based on these results, we focused on LoVo cell line for
the subsequent experiments. Since no satisfactory anti-
Slit2 antibody could be used to detect the endogenous
Slit2 protein expression based on our preliminary study,
the anti-myc antibody was used to detect the secretary
Slit2 protein in the CM from HEK293 cells stably express-
ing Slit2-myc (Fig. 2c).
To investigate potential role of srGAP1 in CRC, we
analyzed its alteration frequency in CRC using an online
database tool (http://www.cbioportal.org/public-portal/
index.do). Based on the data from 3 different CRC
Fig. 1 srGAP1 is downregulated in CRC tissues and correlates with poor survival. a Representative images of IHC staining of srGAP1 in CRC
tissues and adjacent NCTs. b The protein expression of srGAP1 was frequently decreased in 47.5% of CRC tissues compared with paired NCTs.
The staining results of srGAP1 protein were available in 156 CRC and 122 NCT tissues. c Overall survival analysis based on the protein
expression levels of srGAP1 in CRC. CRC patients with low srGAP1 levels (score 0 or 1) had a significantly poorer OS than patients with high
srGAP1 levels (score 2 or 3)
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cohorts, srGAP1 locus was found to be mutated in 4%~
7% CRCs (Fig. 1d), whereas no deletion or amplification
was observed.
srGAP1 is a Robo1-interacting protein in CRC
Previous studies have revealed that srGAP1 could
interact with Robo1 in neuron [10, 12]. To check po-
tential interaction between Robo1 and srGAP1 in CRC
cells, we performed CoIP assay. Plasmids of Robo1-
HA, srGAP1-GFP or empty vector were transfected
into LoVo cells. After IP using an anti-HA antibody,
srGAP1 was detected in the immunoprecipitates of the
cells expressing both Robo1-HA and srGAP1-GFP pro-
teins, but not that of the control cells (Fig. 3a). To fur-
ther confirm it, we performed CoIP using an anti-Flag
antibody in LoVo and HCT116 cells cotranfected with
Robo1-HA, srGAP1-Flag and/or USP33-GFP (also a
Robo1-interacting protein). CoIP results showed that
Robo1 and USP33 could be detected in the immuno-
precipitates of LoVo cells expressing endogenous
Robo1 but not in those of HCT116 cells without en-
dogenous Robo1 expression (Fig. 3b). These results
confirmed that Robo1 could interact with srGAP1 and
USP33 in CRC cells, and srGAP1 could not interact
with USP33 directly.
To check whether srGAP1 show similar subcellular
localization as Robo1 in CRC cells, we performed im-
munofluorescence assay by cotransfecting Robo1-RFP
and srGAP1-GFP plasmids into LoVo cells. As shown in
Fig. 3c, most of Robo1-RFP and srGAP1-GFP were dis-
tributed in the perinuclear compartment, and only a low
ratio of fluorescence (RFP or GFP) was observed at the
plasma membrane in the Mock-treated cells. Whereas
the fluorescence signals become stronger at the plasma
membrane after Slit2 treatment, suggesting that Slit2
could initiate the redistribution of Robo1 and srGAP1 to
Table 2 Univariate and multivariate analyses of OS for the 156 CRC patients
Univariate analysis Multivariate analysis
P HR 95% CI P HR 95% CI
Ages (<64 / ≥64) 0.071 1.567 0.962–2.551
Gender (male/female) 0.404 0.815 0.505–1.317
Tumor size (<5 cm / ≥5 cm) 0.817 0.945 0.585–1.527
Nodal status (negative/positive) 0.000 2.823 1.689–4.719 0.050 0.299 0.089–1.002
Differentiation (well or moderately/poorly) 0.000 3.358 2.004–5.625 0.002 2.442 1.393–4.281
Tumor stage (I + II/ III + IV) 0.000 3.342 1.956–5.711 0.001 7.529 2.167–26.156
srGAP1 expression (low/ high) 0.006 0.487 0.290–0.817 0.070 0.613 0.360–1.041
HR hazard ration, 95%, CI 95% confidence interval
Fig. 2 Slit2 inhibits CRC cell migration in a Robo dependent manner. a The mRNA expression of components in the Slit/Robo signaling in CRC
cell lines. b The protein expressions of Robo1 and srGAP1 in CRC cell lines were detected by western blot, with beta-actin as a loading control.
c Detection of Slit2-myc in slit2 conditional medium (CM). d Mutation at srGAP1 locus was analyzed based on data obtained from the Stand
Up to Cancer cBio portal (http://cbio.mskcc.org/su2c-portal/)
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the plasma membrane, which is consistent with our previ-
ous report [7]. Collectively, IF results show that srGAP1
and Robo1 have similar subcellular localization in the
Slit2-treated CRC cells.
Slit2-Robo1 inhibits Cdc42 activity through srGAP1
Cdc42, a key member of Rho GTPases, could prompt
cell migration by regulating actin cytoskeleton. Previ-
ous work revealed that Slit2 could increase srGAP1-
Robo1 interaction and inactivate Cdc42, resulting in
decreased cell motility in neuronal system [10]. So we
checked the GTPase activity of Cdc42 in LoVo cells
transfected with Slit2, RoboN, srGAP1-GFP, or srG
AP1ΔGAP using GST pull-down assay (Fig. 4a). The
results showed that the ectopic expression of Slit2
decrease the levels of Cdc42-GTP, which could be
blocked by RoboN, suggesting that the effect is medi-
ated by Robo (Fig. 4b). Similar results were obtained
by treatment with Slit2 and RoboN CM (data not
shown).
We then checked the role of srGAP1 in the regula-
tion of Cdc42 by Slit2-Robo1 signaling. As shown in
Fig. 4c, overexpression of srGAP1 could enhance the
inhibitory effect of Slit2 on Cdc42 activity, whereas
inhibiting of srGAP1 could block Slit2-mediated inactiva-
tion of Cdc42. Taken together, these results demonstrate
that Slit2-Robo1 signaling inhibits Cdc42 activity through
srGAP1.
srGAP1 mediates the migration inhibition function of
Slit2 by inactivating Cdc42 activity in CRC
Our previous work reveals that Slit2 inhibits CRC
cell migration in a Robo-dependent manner [7]. To
check whether the inhibitory effect of Slit2 is me-
diated by srGAP1 in CRC, plasmids of srGAP1 or
its dominant negative mutant (srGAP1ΔGAP) were
transfected into LoVo cells. Migration assay showed
that ectopic srGAP1 expression significantly enhanced the
migration inhibition effect of Slit2, whereas srGAP1ΔGAP
blocked it (Fig. 5a-b) in LoVo cells. In addition,
similar results were observed in a Transwell assay
(data not shown). Collectively, these data suggest
that srGAP1 is a key downstream effector of Slit2-
Robo1 signaling.
Further study showed that blocking Cdc42 activity using
a dominant negative form of Cdc42 (DNCdc42) could
Fig. 3 srGAP1 is a Robo1-interacting protein in CRC. a srGAP1 interacted with Robo1. Coimmunoprecipitation was performed to detect the
interaction of Robo1-HA with srGAP1-GFP in LoVo cells transfected with Robo1-HA, srGAP1-GFP. Immunoprecipitates and total cell lysates
(TCL) were immunoblotted with antibodies as indicated. b srGAP1 could indirectly interact with USP33 through Robo1. Coimmunoprecipitation
was performed to detect the interaction of srGAP1-GFP with Robo1, GFP-USP33 in LoVo and HCT116 cells. srGAP1 could interact with USP33 in LoVo
cells expressing endogenetic Robo1 but not in HCT116 cells without endogenetic Robo1 expression. c srGAP1 showed similar subcelluar localization
as Robo1 in Slit2-treated CRC cells
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mimic the migration inhibition effect of Slit2, whereas ec-
topic expression of CACdc42 (constitutively active) could
retrieve the decreased cell motility in Slit2-treated CRC
cells, suggesting that Cdc42 is a major functional target of
Slit2-Robo1-srGAP1 signaling in inhibiting CRC cell
migration (Fig. 5c-d).
Discussion
Slit-Robo signaling plays extensive role in a variety of tis-
sue types besides theirs key role in nervous system [3, 13].
We previously revealed that Slit2 is downregulated in
CRC and inhibits CRC cell migration [7]. In this study, we
revealed that srGAP1 is significantly downregulated in
CRC tissues, and was associated with tumor progression
and survival. Further functional and mechanic analyses
identified that srGAP1 mediates the migration inhibition
function of Slit2 by suppressing Cdc42 activity in CRC.
Slits are important modulators of cell migration both
in neuronal and non-neuronal cells. Previous studies
have showed that Slit2-Robo1 pathway was frequently
inactivated in human cancers, including CRC [7, 8]. Our
previous data showed that Slit2 exerts a migration in-
hibitory role in CRC in a Robo-dependent manner, and
Slit2 is downregulated in CRC due to promoter hyper-
methylation. Similar effect of Slit2 on cell migration of
CRC also has been reported by others [9].
The underlying mechanism that Slit2 regulates tumor
development and progression is very complicated [3].
Several downstream effectors, including Abl [14], Dock
[15], Ena (32), ERK1/2 [16], small Rho GTPases [10],
USP33 [7] and Vilse [17], have been reported to mediate
the inhibitory effect of Slit2-Robo1 signaling on cell motil-
ity, proliferation, apoptosis and angiogenesis in different
cell types.
A role for Rho GTPase-activating proteins in repulsion
mediated by Robo has been shown in neuronal migration
[10] and glioma cell invasion [11]. Small GTPases of the
Rho family, including RhoA, Rac1 and Cdc42, are key
regulators of actin cytoskeletal dynamics in mammals
[18, 19]. These GTPases switch between an inactive
status (GDP-bound) and an active status (GTP-bound),
and guanine nucleotide exchange factors activate Rho
GTPases while GAPs inactivate them. The binding of
Slit2 modifies the cytoplasmic domains of the Robo1,
and prompts the recruitment of srGAP1 to the intracel-
lular domain of Robo1 and the inactivation of Cdc42 in
neuron, suggesting srGAP1-Cdc42 a key regulatory axis
of Slit2-Robo1 signaling in neuronal migration [10]. In
this study, we confirmed that srGAP1 binds to Robo1
in responding to the Slit2 treatment and mediates its
tumor suppressive function in CRC. Interestingly, a re-
cent study reported srGAP1 as a candidate susceptibil-
ity gene in papillary thyroid carcinoma [20], and several
mutations of srGAP1 identified in papillary thyroid
carcinoma resulted in severely impaired ability of srGAP1
to inactivate CDC42. Our analysis also observed srGAP1
Fig. 4 Slit2 inhibits Cdc42 activity through srGAP1. a Purification of GST-PAK1 protein. GST-PAK1 fusion proteins were expressed in E. coli (BL21
strain) and purified using GST-sepharose beads. M: protein marker; Total protein from control BL21 strain(1) and BL21 strain expressing GST-PAK1(2); 3:
Purified GST-PAK1 protein. b Slit2 inhibited Cdc42 activity in a Robo-dependent manner. Ectopic expression of Slit2 inhibited Cdc42 activity
(Cdc42-GTP) in LoVo cells, which could be blocked by ectopic expression of RoboN. GTP-loading of Cdc42 (GTP-Cdc42) in LoVo cell extracts
was pulled down using GST-sepharose beads loaded with GST-PAK1 protein and was detected by Western blot using an anti-Cdc42 antibody.
c Slit2 inhibited Cdc42 activity through srGAP1. Ectopic expression of srGAP1 enhanced the inhibitory effect of Slit2 on the GTPase of Cdc42,
whereas blocking srGAP1 activity by srGAP1ΔGAP rescued the Cdc42-GTP levels in Slit2-overexpressed LoVo cells
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mutations in a fraction of CRC tumors and suggested
potential roles of srGAP1 in CRC tumorigenesis, which
deserves further investigations.
Due to the key regulatory role of Cdc42 in actin cyto-
skeletal dynamics, many studies have demonstrated its
importance in mediating tumor aggression, and propose it
a promising target of cancer therapy [21]. That CDC42
prompts cell motility has been reported in many types
of human cancers [11, 19, 22–30], especially in CRC
[31–34]. In this study, we revealed that Slit2 inhibited
CRC cell migration via repressing Cdc42 activity. When
Robo1 or srGAP1 activity was blocked, the CDC42
activity was rescued in Slit2-treated CRC cells. At the
same time, blocking Cdc42 activity could mimic the
inhibitory effect of Slit2 on CRC migration, whereas
ectopic expression of CACdc42 could retrieve the de-
creased cell motility induced by Slit2. These data clearly
demonstrate that the Slit2-Robo1 signaling inhibits Cdc42
activity and CRC cell motility through srGAP1, confirm-
ing the key functional role of srGAP1-Cdc42 axis in the
Slit2-Robo1 signaling in CRC. In glioma and esophageal
cancer, negative regulation of Slit2 on Cdc42 and cell
Fig. 5 srGAP1 mediates the migration inhibitory function of Slit2 by inhibiting Cdc42 activity in CRC cells. a-b Slit2 inhibits CRC motility through
srGAP1. Ectopic expression of srGAP1 enhanced the inhibitory effect of Slit2 on the migration of LoVo cells, whereas blocking the srGAP1 activity
by srGAP1ΔGAP rescued the migration ability of Slit-treated LoVo cells. c-d Cdc42 is a major functional target of the Slit2-Robo1 signaling in
inhibiting CRC cell migration. Blocking Cdc42 activity using DNCdc42 (dominant negative) mimicked the inhibitory effect of Slit2 on the CRC
cell migration, whereas ectopic expression of CACdc42 (constitutively active) retrieved the decreased cell motility by Slit2 treatment.
*P < 0.001; **P < 0.0001
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migration also had been reported [11, 29], suggesting
Cdc42 a common key target of the Slit2-Robo1 signaling
in human cancers. Based on these data and our previous
study [35], we propose a working model for the Slit2-
Robo1 signaling transduction pathway in CRC cells
(Fig. 6).
Although srGAP1 plays an important role in tumor
progression, little was known about its expression and
clinical significance in human cancers, including CRC.
Our data showed, for the first time, that srGAP1 expression
was significantly downregulated in CRC tissues. Decreased
expression of srGAP1 in CRC tissues was associated
with several key features of tumor aggression and pro-
gression, including lymphatic invasion, tumor diffe-
rentiation and TNM stage. Furthermore, srGAP1 was
identified as a potential predictor for patient survival.
These data were in concordance with its role in mediat-
ing the inhibitory function of Slit2 signaling on the
CRC cell motility and metastasis [7].
Conclusion
In summary, our data revealed that the downregulation
of srGAP1 in CRC tissues is associated with tumor pro-
gression and poor prognosis, and srGAP1-Cdc42 regula-
tory axis is a key downstream target of Slit2-Robo1
pathway in CRC. Slit2-Robo1-srGAP1- Cdc42 pathway
appears to be a promising treatment target for CRC, and
deserves further investigations.
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